Which of the following agents is not used in the treatment of Diabetic Macular Edema/Retinopathy:
**Core Concept**
Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) are complications of diabetes mellitus characterized by abnormal blood-retinal barrier permeability and retinal capillary damage. The treatment aims to reduce inflammation, prevent further damage, and promote healing.
**Why the Correct Answer is Right**
Anti-VEGF (Vascular Endothelial Growth Factor) agents, such as ranibizumab, bevacizumab, and aflibercept, are commonly used in the treatment of DME and DR, as they inhibit angiogenesis and reduce vascular permeability. Corticosteroids, like triamcinolone and dexamethasone, are also used to reduce inflammation and edema. **Option C**, oral hypoglycemic agents (e.g., metformin), are not used in the treatment of DME/DR, as they primarily target systemic glucose control rather than local retinal pathology.
**Why Each Wrong Option is Incorrect**
**Option A:** Anti-VEGF agents are indeed used in DME/DR treatment.
**Option B:** Corticosteroids are commonly used in DME/DR treatment to reduce inflammation and edema.
**Option D:** While laser photocoagulation is used in DR treatment, it's not the best choice for this question, but not the worst either.
**Clinical Pearl / High-Yield Fact**
When managing DME/DR, it's essential to note that anti-VEGF therapy is most effective when combined with tight glycemic control and regular follow-up, as it can lead to rapid improvement in visual acuity.
**Correct Answer:** C. Oral hypoglycemic agents are not used in the treatment of Diabetic Macular Edema/Retinopathy.